Garetosmab reduces lesion formation, volume in patients with rare bone disease (opens in new tab)

CHICAGO — Garetosmab reduced new heterotopic bone lesions in patients with fibrodysplasia ossificans progressiva at 56 weeks compared with placebo, according to results of the OPTIMA trial presented at ENDO 2026.“[Fibrodysplasia ossificans progressiva] is an ultrarare disorder that affects about one in 1 million of the population,” Richard Keen, MD, PhD, director of the Centre for Metabolic Bone Disease, Royal National Orthopaedic Hospital NHS Trust in London, said during a presentation. “It’...